CHP
GNCA

Cable Hill Partners’s Genocea Biosciences, Inc. GNCA Stock Holding History

Cable Hill Partners’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-500
Closed -$6K – 1062
2017
Q3 		$6K Buy
+500
New +$19K ﹤0.01% 736

Other funds holding GNCA

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Cable Hill Partners's GNCA Position: Q4 2017 in Review

Cable Hill Partners sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2017, closing a stake of 500 shares — an estimated $6K sold.

Cable Hill Partners first reported a position in GNCA in Q3 2017 and held it in 1 quarter. The position peaked at $6K in Q3 2017. 56 funds tracked by Wall St. Rank hold GNCA as of Q4 2017.

  • Cable Hill Partners reported no remaining Genocea Biosciences, Inc. position as of Q4 2017 after selling out during the quarter.
  • Cable Hill Partners sold 500 Genocea Biosciences, Inc. shares in Q4 2017, an estimated $6K.
  • Cable Hill Partners first reported a position in Genocea Biosciences, Inc. in Q3 2017 and held it in 1 quarter.
  • Cable Hill Partners's Genocea Biosciences, Inc. position peaked at $6K in Q3 2017.
  • 56 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2017.

Based on Cable Hill Partners's 13F filing for Q4 2017, filed 22 Feb 2018.